AIMS: To confirm by means of pentagastrin, a synthetic gastrin agonist, that netazepide is a gastrin/CCK2 receptor antagonist in healthy subjects, and that antagonism persists during repeated dosing. METHODS: We did two studies in which we infused pentagastrin (0.6 μg kg(-1) h(-1) intravenously), aspirated gastric secretion and measured the volume, pH and H(+) secretion rate of the gastric aspirate. First, we did a double-blind, five-way crossover study (n = 10) to assess the effect of single oral doses of netazepide (1, 5, 25 and 100 mg) and placebo on the response to pentagastrin. Then, we did a single-blind, placebo-controlled study (n = 8) to assess the effect of the first and last oral doses of netazepide (100 mg) twice daily for 13 doses on the response to pentagastrin. RESULTS:Netazepide was well tolerated. After placebo, pentagastrin increased the volume and H(+) secretion rate and reduced the pH of gastric aspirate. Compared with placebo, single doses of netazepide caused dose-dependent inhibition of the pentagastrin response (P < 0.02); netazepide (100 mg) abolished the response. After 13 doses, the reduction in volume and H(+) secretion rate persisted (P < 0.001), but the pH effect was mostly lost. CONCLUSIONS:Netazepide is an orally active, potent, competitive antagonist of human gastrin/CCK2 receptors. Antagonism is dose dependent and persists during repeated dosing, despite tolerance to the effect on pH. Further studies are required to explain that tolerance. Netazepide is a tool to study the physiology and pharmacology of gastrin, and merits studies in patients to assess its potential to treat gastric acid-related conditions and the trophic effects of hypergastrinaemia.
RCT Entities:
AIMS: To confirm by means of pentagastrin, a synthetic gastrin agonist, that netazepide is a gastrin/CCK2 receptor antagonist in healthy subjects, and that antagonism persists during repeated dosing. METHODS: We did two studies in which we infused pentagastrin (0.6 μg kg(-1) h(-1) intravenously), aspirated gastric secretion and measured the volume, pH and H(+) secretion rate of the gastric aspirate. First, we did a double-blind, five-way crossover study (n = 10) to assess the effect of single oral doses of netazepide (1, 5, 25 and 100 mg) and placebo on the response to pentagastrin. Then, we did a single-blind, placebo-controlled study (n = 8) to assess the effect of the first and last oral doses of netazepide (100 mg) twice daily for 13 doses on the response to pentagastrin. RESULTS:Netazepide was well tolerated. After placebo, pentagastrin increased the volume and H(+) secretion rate and reduced the pH of gastric aspirate. Compared with placebo, single doses of netazepide caused dose-dependent inhibition of the pentagastrin response (P < 0.02); netazepide (100 mg) abolished the response. After 13 doses, the reduction in volume and H(+) secretion rate persisted (P < 0.001), but the pH effect was mostly lost. CONCLUSIONS:Netazepide is an orally active, potent, competitive antagonist of humangastrin/CCK2 receptors. Antagonism is dose dependent and persists during repeated dosing, despite tolerance to the effect on pH. Further studies are required to explain that tolerance. Netazepide is a tool to study the physiology and pharmacology of gastrin, and merits studies in patients to assess its potential to treat gastric acid-related conditions and the trophic effects of hypergastrinaemia.
Authors: Simon Almeida-Vega; Krista Catlow; Susan Kenny; Rod Dimaline; Andrea Varro Journal: Am J Physiol Gastrointest Liver Physiol Date: 2008-12-12 Impact factor: 4.052
Authors: J B Adams; R E Pyke; J Costa; N R Cutler; E Schweizer; C S Wilcox; P G Wisselink; M Greiner; M W Pierce; A C Pande Journal: J Clin Psychopharmacol Date: 1995-12 Impact factor: 3.153
Authors: R Fossmark; Ø Sørdal; C S Jianu; G Qvigstad; I S Nordrum; M Boyce; H L Waldum Journal: Aliment Pharmacol Ther Date: 2012-10-16 Impact factor: 8.171
Authors: Malcolm Boyce; Frans van den Berg; Toni Mitchell; Kate Darwin; Steve Warrington Journal: Eur J Clin Pharmacol Date: 2016-10-29 Impact factor: 2.953
Authors: Malcolm Boyce; Andrew R Moore; Liv Sagatun; Bryony N Parsons; Andrea Varro; Fiona Campbell; Reidar Fossmark; Helge L Waldum; D Mark Pritchard Journal: Br J Clin Pharmacol Date: 2016-11-21 Impact factor: 4.335
Authors: Sandeep Nadella; Victor Ciofoaia; Hong Cao; Bhaskar Kallakury; Robin D Tucker; Jill P Smith Journal: Dig Dis Sci Date: 2019-10-09 Impact factor: 3.199
Authors: Andrew R Moore; Malcolm Boyce; Islay A Steele; Fiona Campbell; Andrea Varro; D Mark Pritchard Journal: PLoS One Date: 2013-10-01 Impact factor: 3.240
Authors: Klaire Exarchou; Nathan A Stephens; Andrew R Moore; Nathan R Howes; D Mark Pritchard Journal: Curr Oncol Rep Date: 2022-01-20 Impact factor: 5.075